Search Results - "Barlesi, F"

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches by Reck, M., Carbone, D.P., Garassino, M., Barlesi, F.

“…Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutated RAS isoform…”
Get full text

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Novello, S, Barlesi, F, Califano, R, Cufer, T, Ekman, S, Levra, M Giaj, Kerr, K, Popat, S, Reck, M, Senan, S, Simo, G V, Vansteenkiste, J, Peters, S

Get full text

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report by Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A.

Get full text

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial by Moro-Sibilot, D., Cozic, N., Pérol, M., Mazières, J., Otto, J., Souquet, P.J., Bahleda, R., Wislez, M., Zalcman, G., Guibert, S.D., Barlési, F., Mennecier, B., Monnet, I., Sabatier, R., Bota, S., Dubos, C., Verriele, V., Haddad, V., Ferretti, G., Cortot, A., De Fraipont, F., Jimenez, M., Hoog-Labouret, N., Vassal, G.

“…In 2013, the French National Cancer Institute initiated the AcSé program to provide patients with secure access to targeted therapies outside of their marketed…”
Get full text

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group by Mosele, F., Remon, J., Mateo, J., Westphalen, C.B., Barlesi, F., Lolkema, M.P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., Wagle, N., Stenzinger, A., Bonastre, J., Bayle, A., Michiels, S., Bièche, I., Rouleau, E., Jezdic, S., Douillard, J-Y., Reis-Filho, J.S., Dienstmann, R., André, F.

“…Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been…”
Get full text

Anti-TIGIT therapies for solid tumors: a systematic review by Rousseau, A., Parisi, C., Barlesi, F.

“…Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent…”
Get full text

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry by Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.

“…Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of…”
Get full text

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases by Vokes, E.E., Ready, N., Felip, E., Horn, L., Burgio, M.A., Antonia, S.J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., Waterhouse, D., Domine, M., Garassino, M., Chow, L.Q.M., Blumenschein, G., Barlesi, F., Coudert, B., Gainor, J., Arrieta, O., Brahmer, J., Butts, C., Steins, M., Geese, W.J., Li, A., Healey, D., Crinò, L.

“…Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival…”
Get full text

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial by Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., Lynch, T.J.

“…Ipilimumab, an anti-CTLA4 monoclonal antibody, demonstrated survival benefit in melanoma with immune-related (ir) adverse events (irAEs) managed by the…”
Get full text

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus by Curigliano, G., Banerjee, S., Cervantes, A., Garassino, M.C., Garrido, P., Girard, N., Haanen, J., Jordan, K., Lordick, F., Machiels, J.P., Michielin, O., Peters, S., Tabernero, J., Douillard, J.Y., Pentheroudakis, G., Addeo, A., Albiges, L., Ascierto, P.A., Banerjee, S., Barlesi, F., Caldas, C., Cardoso, F., Cervantes, A., Chaberny, I.F., Cherny, N.I., Choueiri, T.K., Chua, M.L.K., Criscitiello, C., Curigliano, G., de Azambuja, E., De Ruysscher, D., de Vries, E., Dent, R., Douillard, J.Y., D’Ugo, D., Dziadziuszko, R., Faivre-Finn, C., Felip, E., Garassino, M., Garrido, P., Girard, N., Glynne-Jones, R., Golfinopoulos, V., Haanen, J., Hamilton, E., Jänne, P.A., Jordan, K., Kanesvaran, R., Kim, S.B., Liebert, U.G., Lordick, F., Machiels, J.P., Michielin, O., Mok, T.S.K., Morgan, G., Obermannova, R., Park, K., Passaro, A., Pentheroudakis, G., Peters, S., Reck, M., Salazar Soler, R., Scotté, F., Senan, S., Sessa, C., Smyth, E., Soo, R., Soria, J.C., Spicer, J., Strasser, F., Tabernero, J., Tan, D.S.W., Trapani, D., Van Cutsem, E., van Halteren, H., van Schil, P.E., Veronesi, G., Yang, J.

“…We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer…”
Get full text

Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess by Ciccolini, J., Barbolosi, D., André, N., Benzekry, S., Barlesi, F.

Get full text

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort by Mazières, J., Barlesi, F., Filleron, T., Besse, B., Monnet, I., Beau-Faller, M., Peters, S., Dansin, E., Früh, M., Pless, M., Rosell, R., Wislez, M., Fournel, P., Westeel, V., Cappuzzo, F., Cortot, A., Moro-Sibilot, D., Milia, J., Gautschi, O.

“…HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1–2% of lung adenocarcinomas. There is, to date, no standard of care…”
Get full text

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program by Leduc, C., Merlio, J.P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P.P., Monnet, I., Rouquette, I., Fraboulet-Moreau, S., Lemoine, A., Pouessel, D., Mosser, J., Vaylet, F., Langlais, A., Missy, P., Morin, F., Moro-Sibilot, D., Cadranel, J., Barlesi, F., Beau-Faller, M.

“…EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated…”
Get full text

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) by Barlesi, F., Gervais, R., Lena, H., Hureaux, J., Berard, H., Paillotin, D., Bota, S., Monnet, I., Chajara, A., Robinet, G.

“…Brain metastases (BM) occur in up to 40% of non-small-cell lung cancer (NSCLC) patients. This trial assessed the safety and efficacy of pemetrexed–cisplatin in…”
Get full text

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF) by Couraud, S., Cortot, A.B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappé, P., Ferretti, G.R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., Milleron, B.

“…Despite advances in cancer therapy, mortality is still high except in early-stage tumors, and screening remains a challenge. The randomized National Lung…”
Get full text

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors by Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F., Le Loarer, F., Chaput, N., Danlos, F.-X., Planchard, D., Even, C., Khettab, M., Tselikas, L., Besse, B., Barlesi, F., Soria, J.-C., Marabelle, A., Bessede, A., Italiano, A.

“…The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do…”
Get full text

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial by Barlesi, F., Scherpereel, A., Gorbunova, V., Gervais, R., Vikström, A., Chouaid, C., Chella, A., Kim, J.H., Ahn, M.J., Reck, M., Pazzola, A., Kim, H.T., Aerts, J.G, Morando, C., Loundou, A., Groen, H.J.M., Rittmeyer, A.

“…The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous nonsmall-cell…”
Get full text

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies by Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J.-M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., Colomba, E.

Get full text

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group by Mosele, M F, Westphalen, C B, Stenzinger, A, Barlesi, F, Bayle, A, Bièche, I, Bonastre, J, Castro, E, Dienstmann, R, Krämer, A, Czarnecka, A M, Meric-Bernstam, F, Michiels, S, Miller, R, Normanno, N, Reis-Filho, J, Remon, J, Robson, M, Rouleau, E, Scarpa, A, Serrano, C, Mateo, J, André, F

“…Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the…”
Get more information

Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges by Saini, K.S., Svane, I.M., Juan, M., Barlesi, F., André, F.

Get full text